XML 27 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
Valuation and Qualifying Accounts
 12 Months Ended
Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Valuation and Qualifying Accounts
Schedule II
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES
Valuation and Qualifying Accounts
Years ended December 31, 2024 and 2023.
Description
Balance at
beginning of
period
Charged to
costs and
expenses
Charged to
other
accounts
Deductions
Balance at
end of period
Allowance for uncollectible amounts, cash discounts, chargebacks, and credits issued for damaged products:
For the years ended
December 31:
2023596,091 5,953,142 — (5,969,671)
(1)
579,562 
2024579,562 5,734,792 104,000 (5,381,391)1,036,963 
Valuation allowance for deferred tax assets:
For the years ended
December 31:
202321,557,784 311,544 — — 21,869,328 
202421,869,328 80,060 21,949,388 
(1) Composed of actual returns and credits for chargebacks and cash discounts.